7.065
7.34%
-0.545
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $7.065, with a volume of 3.50M.
It is down -7.34% in the last 24 hours and up +2.49% over the past month.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$7.61
Open:
$7.55
24h Volume:
3.50M
Relative Volume:
1.32
Market Cap:
$519.17M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-4.3344
EPS:
-1.63
Net Cash Flow:
$-71.49M
1W Performance:
-4.06%
1M Performance:
+2.49%
6M Performance:
-11.97%
1Y Performance:
+188.99%
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ALT | 7.065 | 519.17M | 409.00K | -101.35M | -71.49M | -1.63 |
VRTX | 467.45 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.78 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.72 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.44 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.44 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
Jan-24-24 | Initiated | Goldman | Neutral |
Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
Dec-01-22 | Initiated | Goldman | Buy |
Dec-29-21 | Resumed | Jefferies | Buy |
Jun-02-21 | Initiated | H.C. Wainwright | Buy |
Feb-11-21 | Initiated | Guggenheim | Buy |
Dec-14-20 | Initiated | Jefferies | Buy |
Nov-12-20 | Reiterated | B. Riley Securities | Buy |
Sep-25-20 | Initiated | B. Riley FBR | Buy |
Aug-14-20 | Initiated | Evercore ISI | Outperform |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
Feb-24-20 | Resumed | ROTH Capital | Buy |
Jul-19-19 | Initiated | ROTH Capital | Buy |
Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
HC Wainwright Decreases Earnings Estimates for Altimmune - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(ALT) Trading Report - Stock Traders Daily
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha
Altimmune Unusual Options Activity For November 13 - Benzinga
Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha
Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey
UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq
GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India
Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance
Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart
Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks
Altimmune Stock Rallies 30% on Updates - citybiz
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat
Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com
Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks
UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Altimmune Appoints Greg Weaver as CFO - citybiz
Altimmune Appoints Chief Financial Officer - Contract Pharma
Altimmune says ‘something raised attention of FDA’ - TipRanks
Altimmune appoints Greg Weaver as CFO - TipRanks
Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St
Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa
Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha
Altimmune advances obesity treatment into Phase 3 trials - Investing.com India
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times
Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
Garg Vipin K | President and CEO |
Jan 30 '24 |
Option Exercise |
0.00 |
26,775 |
0 |
276,030 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):